Roche's Genentech Inc. reported positive top-line results for Hemlibra (emicizumab-kxwh) in the treatment of hemophilia A patients who do not have inhibitors of factor VIII and the data appear to boost the newly approved product's competitive position against the high-cost standard of care.
Detailed data from the Phase III HAVEN 3 clinical trial, which will be presented at a future medical meeting, may...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)